RareCyte

About

RareCyte develops advanced spatial biology and liquid biopsy technologies that deliver the reliable data researchers need to accelerate biomarker development and advance precision biology at clinical scale. The company was founded in 2009 by Ron Seubert and spun out of Applied Precision Inc. after GE Healthcare acquired API in 2011. Headquartered in Seattle, Washington, RareCyte has grown to become a leader in precision biology, providing integrated platforms that combine instruments, consumables, and reagents for biomedical research, drug development, and next-generation diagnostics. The company's core platforms include Orion, a high-plex spatial biology platform capable of 20-channel whole-slide multiplex imaging in a single round, and CyteFinder, a liquid biopsy platform designed for rare circulating tumor cell detection with approximately 1000 times greater sensitivity than flow cytometry. RareCyte serves over 100 biopharma companies and leading academic institutions worldwide, supporting biomarker development across diverse indications. The company operates a CLIA-accredited laboratory following GLP guidelines and holds ISO 13485:2016 accreditation for product manufacturing, making it a trusted partner for clinical trial biomarker testing and translational research programs.